KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies

Survival of patients with metastatic CRC (mCRC) has improved steadily over the past several decades, due largely to the development of new combinations of standard chemotherapy, as well as to the introduction of new targeted therapies. Among the available targeted therapies are two monoclonal antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Soulières, D., Greer, W., Magliocco, Anthony M., Huntsman, D., Young, S., Tsao, M.-S., Kamel-Reid, S.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2010
Materias:
Medical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901795/
https://www.ncbi.nlm.nih.gov/pubmed/20680106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901795/
https://www.ncbi.nlm.nih.gov/pubmed/20680106

Ejemplares similares